Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pixantrone - Servier

Drug Profile

Pixantrone - Servier

Alternative Names: BBR-2278; BBR-2778; Pixantrone dimaleate; Pixuvri

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Vermont
  • Developer Cell Therapeutics; Neopharm Ltd; Servier
  • Class Anthracyclines; Anthraquinones; Antineoplastics; Isoquinolines; Small molecules
  • Mechanism of Action Alkylating agents; Immunosuppressants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-Hodgkin's lymphoma
  • Phase III Diffuse large B cell lymphoma; Follicular lymphoma
  • No development reported Cancer
  • Discontinued Breast cancer; Myasthenia gravis

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for phase-I development in Cancer(In adolescents, In children, In infants, Monotherapy, Second-line therapy or greater, In adults) in USA (IV)
  • 01 Oct 2019 Servier acquires pixantrone from CTI Biopharma
  • 13 Jun 2019 The European Commission approves conversion of conditional approval of pixantrone (Monotherapy, Second-line therapy or greater) for Non-Hodgkin's lymphoma into a standard marketing authorisation in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top